商业与经济
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
来源: Business News · 发布于
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
相关报道
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.
Business News ·
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Business News ·
Stopping Ozempic may raise heart attack and stroke risk
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compar
All Top News -- ScienceDaily ·
The ecstasy of buying our first home was short-lived after we found 150 faults
Getting the keys to a new home felt like a dream come true, until this couple found 150 faults.
feeds.bbci.co.uk ·
Here's exactly what Paramount promised Hollywood to land WBD — and why some are still skeptical
Paramount CEO David Ellison's antitrust settlement eased some theatrical concerns, but questions remain about what happens when the five-year agreement ends.
Business News ·